Adicet Bio, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 29.49 million compared to USD 29.88 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.72 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.315 USD | -2.59% | -9.03% | -30.69% |
Jun. 05 | Sector Update: Health Care Stocks Rise Wednesday Afternoon | MT |
Jun. 05 | Adicet Bio Says US FDA Grants Fast Track Designation for ADI-001 to Treat Lupus Nephritis | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.69% | 111M | |
+48.75% | 57.87B | |
+41.65% | 40.25B | |
-7.34% | 39.94B | |
-5.96% | 28.54B | |
+12.43% | 26.4B | |
-20.12% | 19.33B | |
+30.27% | 12.4B | |
-0.69% | 12.23B | |
+24.79% | 12.2B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023